Quintiles Consulting, a provider of product development, regulatory and market strategies to the pharmaceutical, biotechnology and medical device industries, has announced a new research partnership with the Institute for Life Sciences Business Economics (iLSBE) at the Erasmus University of Rotterdam, Netherlands.
The accord will drive innovation in health care product pricing, reimbursement, market access and sales strategies by combining the academic strength of the iLSBE with the practical experience and insight of Quintiles and its clients. Through the partnership, the two organizations will jointly identify new areas for business economics research based on Quintiles' first-hand knowledge of industry challenges and the cutting-edge academic research capabilities of the iLSBE.
"This academic partnership will provide Quintiles' clients with access to pioneering, practical research at a time when innovative approaches to pricing and reimbursement, as well as marketing and sales, are needed to meet growing pressure from public and private payers alike," said Jacco Keja, vice president of Quintiles Consulting, Managed Markets. "Combining this strong academic backing with the depth and expertise of the world's largest contract research and sales organization gives us a truly unique client offering spanning the entire product lifecycle," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze